"Bribery" is the word on everyone's mind in China as the GlaxoSmithKline ($GSK) bribery probe deepens and expands out toward other drugmakers. Big Pharma companies are fighting to stay out of the spotlight as authorities show up to visit them. But Thursday, Baxter International ($BAX) found itself in the hot seat for expense violations it found last year. Story